Astellas Pharma Inc. ADR | |
Stock Exchange | Other OTC |
EPS |
$1.03 |
Market Cap |
$26.05 B |
Shares Outstanding |
1.89 B |
Public Float |
- |
Astellas Pharma Inc. | |
Stock Exchange | Other OTC |
EPS |
$1.03 |
Market Cap |
$26.15 B |
Shares Outstanding |
1.98 B |
Public Float |
- |
Astellas Pharma Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.98 B |
Public Float |
- |
Astellas Pharma Inc. | |
Stock Exchange | Tokyo Stock Exchange |
EPS |
JPY115.01 |
Market Cap |
JPY2.84 T |
Shares Outstanding |
1.89 B |
Public Float |
1.8 B |
Address |
2-5-1 Nihonbashi-Honcho Tokyo Tokyo 103 Japan |
Employees | - |
Website | http://www.astellas.com |
Updated | 07/08/2019 |
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. |